Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
Purpose
The purpose of this observational study is to learn about the HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer. The main question it aims to answer is: - Does the heterogeneity of HER2 expression level and spatial distribution in different tissues affect the efficacy of trastuzumab deruxtecan in metastatic breast cancer?
Condition
- Metastatic Breast Cancer
Eligibility
- Eligible Ages
- Between 18 Years and 80 Years
- Eligible Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients with advanced or locally unresectable breast cancer; - Treated with T-DXd (DS-8201, trastuzumab deruxtecan) regardless of line of therapy, HR, and HER2 expression level; - HER2 immunohistochemistry staining information of the primary lesion or metastatic/recurrent lesion; - Measurable lesions with treatment response results that can be evaluated through imaging examinations; - Able to follow up with the latest progression-free survival or overall survival.
Exclusion Criteria
- Patients with missing basic clinical information or HER2 immunohistochemistry staining information; - Patients with missing pathological results for both primary and metastatic/recurrent lesions; - Patients with no measurable lesions and unable to evaluate T-DXd treatment response; - Discontinue T-DXd therapy for unacceptable adverse events or other reasons; - Patients lost to follow-up after T-DXd treatment.
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Trastuzumab Deruxtecan |
|
Recruiting Locations
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts 02215
Boston, Massachusetts 02215
More Details
- NCT ID
- NCT06551220
- Status
- Recruiting
- Sponsor
- Sun Yat-sen University